A recent article 1 published in Circulation investigated cardiopulmonary exercise testing with a primary aim of comparing patients who were or were not taking ␤-blockers at the time of the exercise test. The authors' limitations did not mention the tracking of medication profiles during follow-up. It is likely, especially at a tertiary care center and during the early ␤-blocker era, that patients who were assigned to the no-␤-blocker group at the time of testing were prescribed ␤-blockers shortly thereafter.
Response
We agree with Mr Bard that lack of information about medication use after stress testing is a potential limitation of our study. If, as he suggests, patients not taking ␤-blockers were later treated with them, these patients would come to resemble those patients who were taking ␤-blockers initially. This greater similarity over time would be expected to diminish any differences between the groups, probably resulting in our underestimating the enhanced prognostic value of peak V O 2 in ␤-blockertreated patients.
We also agree with Mr Bard that the V E/V CO 2 slope is a better measure than peak V E/V CO 2 . Unfortunately, we have been unable, despite a number of attempts, to retrieve from the metabolic carts the data needed to calculate the slope. We thank Mr Bard for pointing out a transcription error. As noted in our previous publication stemming from these data, 1 the mean value for peak V E/V CO 2 was 33Ϯ10, not 29Ϯ10 as we reported. We have confirmed the accuracy of all of the other data in our article, including the poor prognostic value of peak V E/V CO 2 as compared with peak V O 2 . Still, as Mr Bard notes, this value is less than what we reported earlier on a much smaller sample of non-␤-blockers with patients who underwent testing nearly 10 years ago. 2 We suspect that the decline in V E/V CO 2 noted over time may be caused by our changing practice of stressing maximal compensation of congestion before stress testing. Evidence of this is the higher rate of diuretic use in the more contemporary cohort of non-␤-blockers patients (87% versus 79%).
Although we are in complete agreement with Mr Bard that it would have been ideal to have had detailed posttesting data on ␤-blocker use as well as actual V E/V CO 2 slopes as opposed to only peak values, neither of these issues have an impact on the main finding of our article. ␤-Blocker use does not adversely affect the ability of peak V O 2 to predict mortality in patients with severe systolic heart failure.
